Filing Flows › Elite Pharmaceuticals (ELTP) › Q4 FY26 › vs Q3 FY26
Elite Pharmaceuticals (ELTP) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Elite Pharmaceuticals's revenue rose $9.2M (+29%) from $31.6M in Q3 FY26 to $40.7M in Q4 FY26. The biggest changes: Manufacturing +$9.1M (+29%); Licensing +$90K (+44%). Gross margin 51.0% against 41.0% (+10.0 pts).
Elite Pharmaceuticals, Q4 FY26: revenue $40.7M (+27% year over year), operating margin 25.0%, net earnings $18.5M, operating cash flow $9.1M. The chart draws each line against Q3 FY26, the increases inside each band.
Margins
| Q4 FY26 | Q3 FY26 | Change | |
|---|---|---|---|
| Gross margin | 51.0% | 41.0% | +10.0 pts |
| Operating margin | 25.0% | 28.5% | -3.5 pts |
| Net margin | 45.3% | 58.9% | -13.6 pts |
| Free cash flow margin | 21.5% | -17.4% | +38.8 pts |
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Manufacturing | $40.5M | $31.4M | $9.1M | +29% |
| Licensing | $296K | $206K | $90K | +44% |
| Revenue | $40.7M | $31.6M | $9.2M | +29% |
| Gross profit | $20.8M | $13.0M | $7.8M | +60% |
| Cost of revenue | $20.0M | $18.6M | $1.3M | +7% |
| Other income, net | $10.7M | $11.8M | −$1.2M | -10% |
| Operating profit | $10.2M | $9.0M | $1.2M | +13% |
| Operating expenses | $10.6M | $3.9M | $6.6M | +169% |
| Pre-tax earnings | $20.9M | $20.8M | $21K | +0.1% |
| Research & development | $1.6M | $1.0M | $601K | +58% |
| General & admin | $7.7M | $2.5M | $5.2M | +212% |
| Other operating costs | $1.2M | $433K | $813K | +188% |
| Net earnings | $18.5M | $18.6M | −$133K | -0.7% |
| Income tax | $2.4M | $2.2M | $154K | +7% |
| Depreciation & amortization | $252K | $269K | −$17K | -6% |
| Share-based compensation | $29K | $45K | −$16K | -35% |
| Working capital & other | $9.6M | $24.2M | −$14.6M | -60% |
| Operating cash flow | $9.1M | −$5.3M | $14.4M | — |
| Free cash flow (OCF − capex) | $8.7M | −$5.5M | $14.2M | — |
| Capital expenditures | $398K | $206K | $192K | +93% |
Questions
How much did Elite Pharmaceuticals's revenue grow quarter over quarter in Q4 FY26?
Elite Pharmaceuticals's revenue rose $9.2M (+29%) from $31.6M in Q3 FY26 to $40.7M in Q4 FY26.
What drove Elite Pharmaceuticals's revenue change in Q4 FY26?
Manufacturing +$9.1M (+29%); Licensing +$90K (+44%).